Interstitial Lung Disease Pipeline Insight: 120+ Companies, 120+ Therapies in Development

Strategic Insights -

The Interstitial Lung Disease pipeline is a rapidly evolving space with 120+ active players working to develop 120+ pipeline therapies for treatment. DelveInsight's report provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Interstitial Lung Disease Therapeutics Market. The report covers the pipeline drug profiles, including clinical and nonclinical stage products, and provides detailed insights into the key companies involved in targeted therapeutics development.

Key Takeaways:

  • DelveInsight's Interstitial Lung Disease pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Interstitial Lung Disease treatment.
  • Key Interstitial Lung Disease companies such as Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, Bristol-Myers Squibb, Prometheus Biosciences, HEC Pharm, Bayer, Insmed, Avalyn Pharma, PureTech Health, Novartis. Horizon, MediciNova, Endeavor BioMedicines, Pliant Therapeutics, Kadmon Pharmaceuticals, GenKyoTex, Lung Therapeutics. AdAlta, Ark Biosciences, and others are evaluating new drugs for Interstitial Lung Disease to improve the treatment landscape.
  • Promising Interstitial Lung Disease pipeline therapies in various stages of development include DWN12088, LYT-100, BMS-986278, and others.
  • The report provides detailed insights into the key companies that are developing therapies in the Interstitial Lung Disease Market.
  • The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Interstitial Lung Disease treatment.
  • It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Interstitial Lung Disease market.

Statistics:

  • 120+ active players working to develop 120+ pipeline therapies for Interstitial Lung Disease treatment.
  • Over 200+ products under different phases of clinical development, including 47 late-stage products (Phase III), 40 mid-stage products (Phase II), and 45 early-stage products (Phase I).
  • 12 companies have a Phase III-stage pipeline, with Pfizer standing out as the most advanced player.
  • 3 companies have a Phase II-stage pipeline.
  • 15 companies have a Phase I-stage pipeline.
  • 4 companies have a preclinical-stage pipeline.

Sources:

  • DelveInsight's "Interstitial Lung Disease Pipeline Insight, 2025" report.
  • DelveInsight's "Interstitial Lung Disease Pipeline Insight, 2024" report.
  • M2 PressWIRE-July 11, 2025-: Interstitial Lung Disease Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Roche, aTyr Pharma, Boehringer Ingelheim, FibroGen, LTT Bio-Pharma, BMS (C)1994-2025 M2 COMMUNICATIONS RDATE:10072025.